‘1+3 will also impact Korea’s patent linkage system'
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.11.17 05:50:42
가나다라
0
Myung-Hee Lee, senior researcher at KIIP states so at the Medical Intellectual Property Policy Forum…” is analyzing the impact of the 1+3 system”
“Simultaneous filing of patent challenges will decrease…will strengthen practicality in protecting the exclusivity of first generics”
“Amendment to the patent term extension system will be helpful to generic companies” The key is in whether the bill can pass the National Assembly
The so-called ‘1+3 restriction on bioequivalence testing’ system is expected to impact the Drug Approval-Patent Linkage System as well.
If applied, the 1+3 system is expected to eradicate the practice of multiple generic companies jointly filing patent challenges and improve the practicality of the first generic exclusivity right (first generic exclusivity).
Also, the ‘Bill for the Amendment to the Drug Patent Term Extension System’ that is pending at the National Assembly is expected to have a positive effect on generic companies that challenge the original drug’s patent. However, there is also a possibility that this bill will not be passed due to the nearing end of the 2
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)